TY - JOUR
T1 - External Beam Radiation Therapy Followed by Interstitial Radiotherapy with Iridium-192 for Solitary Bladder Tumours
T2 - Results of 111 Treated Patients
AU - van Onna, Ilze E.W.
AU - Oddens, Jorg R.
AU - Kok, Esther T.
AU - van Moorselaar, R. Jeroen A.
AU - Bosch, J. L.H.Ruud
AU - Battermann, Jan J.
AU - Kok, E.J.
PY - 2009/7
Y1 - 2009/7
N2 - Background: Evaluation of bladder-preserving treatment protocol. Objective: To evaluate the long-term results of iridium-192 brachytherapy-based bladder-sparing treatment strategy in patients with solitary invasive bladder tumours. Design, setting, and participants: We performed a retrospective analysis of 111 patients with solitary T1G3-T2Gall bladder tumours (≤5 cm), who were treated with iridium-afterloading brachytherapy between February 1988 and May 2007. Intervention: After transurethral tumour resection, external beam radiotherapy (28 Gy; 12 fractions) was given, followed by brachytherapy (Iridium-192; 40 Gy). Partial cystectomy was part of the treatment strategy in nine patients. In five of those patients a T3 tumour was found, and they were included in the analysis. Measurements: The 5-, 10- and 15-yr overall survival rate (OS); disease-specific survival rate (DSS); and disease-free survival rate (DFS) estimates were determined using the Kaplan-Meier method. Results and limitations: Mean follow-up period was 6.2 yr (range: 0.2-16.3 yr). At the last follow-up 75 patients were alive without evidence of disease, whereas 17 patients had died without evidence of disease. Nineteen patients died of bladder cancer after a mean follow-up period of 2.9 yr (range: 0.5-9.0). OS rates at 5 yr, 10 yr, and 15 yr were 70%, 55%, and 51%, respectively. DSS rates at 5 yr, 10 yr, and 15 yr were 82%, 73% and 73%, respectively. DFS rates at 5 yr, 10 yr, and 15 yr were 60%, 47%, and 23%, respectively. Higher tumour stage (T3 vs T1) was negatively associated with DSS (hazard ratio [HR]:19.8; p = 0.01) and DFS (HR: 4.67; p = 0.02). No prognostic factor was found for OS. Local recurrence occurred in 27% of patients and salvage cystectomy was performed in 9% of patients. Bladder function was able to be preserved in 99 of 111 patients (89%). Conclusions: In patients with solitary stage T1-T2 bladder cancer (≤5 cm) who refuse radical cystectomy or who are poor candidates for major surgical procedures, this modality is a valuable treatment alternative.
AB - Background: Evaluation of bladder-preserving treatment protocol. Objective: To evaluate the long-term results of iridium-192 brachytherapy-based bladder-sparing treatment strategy in patients with solitary invasive bladder tumours. Design, setting, and participants: We performed a retrospective analysis of 111 patients with solitary T1G3-T2Gall bladder tumours (≤5 cm), who were treated with iridium-afterloading brachytherapy between February 1988 and May 2007. Intervention: After transurethral tumour resection, external beam radiotherapy (28 Gy; 12 fractions) was given, followed by brachytherapy (Iridium-192; 40 Gy). Partial cystectomy was part of the treatment strategy in nine patients. In five of those patients a T3 tumour was found, and they were included in the analysis. Measurements: The 5-, 10- and 15-yr overall survival rate (OS); disease-specific survival rate (DSS); and disease-free survival rate (DFS) estimates were determined using the Kaplan-Meier method. Results and limitations: Mean follow-up period was 6.2 yr (range: 0.2-16.3 yr). At the last follow-up 75 patients were alive without evidence of disease, whereas 17 patients had died without evidence of disease. Nineteen patients died of bladder cancer after a mean follow-up period of 2.9 yr (range: 0.5-9.0). OS rates at 5 yr, 10 yr, and 15 yr were 70%, 55%, and 51%, respectively. DSS rates at 5 yr, 10 yr, and 15 yr were 82%, 73% and 73%, respectively. DFS rates at 5 yr, 10 yr, and 15 yr were 60%, 47%, and 23%, respectively. Higher tumour stage (T3 vs T1) was negatively associated with DSS (hazard ratio [HR]:19.8; p = 0.01) and DFS (HR: 4.67; p = 0.02). No prognostic factor was found for OS. Local recurrence occurred in 27% of patients and salvage cystectomy was performed in 9% of patients. Bladder function was able to be preserved in 99 of 111 patients (89%). Conclusions: In patients with solitary stage T1-T2 bladder cancer (≤5 cm) who refuse radical cystectomy or who are poor candidates for major surgical procedures, this modality is a valuable treatment alternative.
KW - Bladder cancer
KW - Bladder preservation
KW - Brachytherapy
KW - Interstitial radiotherapy
KW - Iridium 192
UR - http://www.scopus.com/inward/record.url?scp=67349201379&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.eururo.2008.07.043
DO - https://doi.org/10.1016/j.eururo.2008.07.043
M3 - Article
C2 - 18722048
SN - 0302-2838
VL - 56
SP - 113
EP - 122
JO - European Urology
JF - European Urology
IS - 1
ER -